David A. Mankoff

David A. Mankoff

Auto-generated profile, based on publicly available information

David A. Mankoff

Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2016 in Cancer Research
Verified
Journal Article
Open access
PDF file
BTBruce J. Tromberg
Bruce J. Tromberg
ZZZheng Zhang
Zheng Zhang
ALAnaïs Leproux
Anaïs Leproux
TOThomas O'Sullivan
Thomas O'Sullivan
ACAlbert E. Cerussi
Albert E. Cerussi
DMDavid Mankoff
David Mankoff
The prospective multicenter ACRIN 6691 trial was designed to evaluate whether changes from baseline to mid-therapy in a diffuse optical spectroscopic imaging (DOSI)–derived imaging endpoint, the tissue optical index (TOI), predict pathologic complete response (pCR) in women undergoing breast cancer neoadjuvant chemotherapy (NAC). DOSI instruments were constructed at the University of California, Irvine (Irvine, CA), and delivered to six institutions where 60 subjects with newly diagnosed breast tumors (at least 2 cm in the longest dimension) were enrolled over a 2-year period. Bedside DOSI images of the tissue concentrations of deoxy-hemoglobin (ctHHb), oxy-hemoglobin (ctHbO2), water (ctH2O), lipid, and TOI (ctHHb × ctH2O/lipid) were acquired on both breasts up to four times during NAC treatment: baseline, 1-week, mid-point, and completion. Of the 34 subjects (mean age 48.4 ± 10.7 years) with complete, evaluable data from both normal and tumor-containing breast, 10 (29%) achieved pCR as determined by central pathology review. The percent change in tumor-to-normal TOI ratio (%TOITN) from baseline to mid-therapy ranged from −82% to 321%, with a median of −36%. Using pCR as the reference standard and ROC curve methodology, %TOITN AUC was 0.60 (95% CI, 0.39–0.81). In the cohort of 17 patients with baseline tumor oxygen saturation (%StO2) greater than the 77% population median, %TOITN AUC improved to 0.83 (95% CI, 0.63–1.00). We conclude that the combination of baseline functional properties and dynamic optical response shows promise for clinical outcome prediction. Cancer Res; 76(20); 5933–44. ©2016 AACR.

16 April 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MMMehran Makvandi
Mehran Makvandi
APAustin Pantel
Austin Pantel
LSLauren Schwartz
Lauren Schwartz
ESErin Schubert
Erin Schubert
KXKuiying Xu
Kuiying Xu
LLLilie L. Lin
Lilie L. Lin
BACKGROUND. Poly(ADP-ribose) polymerase (PARP) inhibitors are effective in a broad population of patients with ovarian cancer; however, resistance caused by low enzyme expression of the drug target PARP-1 remains to be clinically evaluated in this context. We hypothesize that PARP-1 expression is variable in ovarian cancer and can be quantified in primary and metastatic disease using a novel PET imaging agent. METHODS. We used a translational approach to describe the significance of PET imaging of PARP-1 in ovarian cancer. First, we produced PARP1-KO ovarian cancer cell lines using CRISPR/Cas9 gene editing to test the loss of PARP-1 as a resistance mechanism to all clinically used PARP inhibitors. Next, we performed preclinical microPET imaging studies using ovarian cancer patient–derived xenografts in mouse models. Finally, in a phase I PET imaging clinical trial we explored PET imaging as a regional marker of PARP-1 expression in primary and metastatic disease through correlative tissue histology. RESULTS. We found that deletion of PARP1 causes resistance to all PARP inhibitors in vitro, and microPET imaging provides proof of concept as an approach to quantify PARP-1 in vivo. Clinically, we observed a spectrum of standard uptake values (SUVs) ranging from 2–12 for PARP-1 in tumors. In addition, we found a positive correlation between PET SUVs and fluorescent immunohistochemistry for PARP-1 (r 2 = 0.60). CONCLUSION. This work confirms the translational potential of a PARP-1 PET imaging agent and supports future clinical trials to test PARP-1 expression as a method to stratify patients for PARP inhibitor therapy. TRIAL REGISTRATION. Clinicaltrials.gov NCT02637934. FUNDING. Research reported in this publication was supported by the Department of Defense OC160269, a Basser Center team science grant, NIH National Cancer Institute R01CA174904, a Department of Energy training grant DE-SC0012476, Abramson Cancer Center Radiation Oncology pilot grants, the Marsha Rivkin Foundation, Kaleidoscope of Hope Foundation, and Paul Calabresi K12 Career Development Award 5K12CA076931.

15 June 2016 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
GLGeraldine J. Liao
Geraldine J. Liao
ACAmy S. Clark
Amy S. Clark
ESErin K. Schubert
Erin K. Schubert
DMDavid A. Mankoff
David A. Mankoff
Estrogen receptor (ER) expression in breast cancer is associated with a more favorable prognosis and necessary for response to endocrine therapies. Traditionally, ER expression is assessed by in vitro assays on biopsied tumor tissue. However, recent advances have allowed in vivo evaluation of ER expression with 18F-fluoroestradiol (18F-FES) positron emission tomography (PET). Clinical studies have demonstrated the use of 18F-FES-PET as a method for quantifying in vivo ER expression and explored its potential as a predictive assay and method of assessing in vivo pharmacodynamic response to endocrine therapy. This review outlines the biology and pharmacokinetics of 18F-FES, highlights the current experience with 18F-FES in patient studies in breast cancers and other diseases, and discusses potential clinical applications and possible future clinical use of 18F-FES-PET.

14 March 2017 in Cancer Research
Verified
Journal Article
Open access
PDF file
RZRong Zhou
Rong Zhou
APAustin R. Pantel
Austin R. Pantel
SLShihong Li
Shihong Li
BLBrian P. Lieberman
Brian P. Lieberman
KPKarl Ploessl
Karl Ploessl
DMDavid A. Mankoff
David A. Mankoff
Glutaminolysis is a metabolic pathway adapted by many aggressive cancers, including triple-negative breast cancers (TNBC), to utilize glutamine for survival and growth. In this study, we examined the utility of [18F](2S,4R)4-fluoroglutamine ([18F]4F-Gln) PET to measure tumor cellular glutamine pool size, whose change might reveal the pharmacodynamic (PD) effect of drugs targeting this cancer-specific metabolic pathway. High glutaminase (GLS) activity in TNBC tumors resulted in low cellular glutamine pool size assayed via high-resolution 1H magnetic resonance spectroscopy (MRS). GLS inhibition significantly increased glutamine pool size in TNBC tumors. MCF-7 tumors, with inherently low GLS activity compared with TNBC, displayed a larger baseline glutamine pool size that did not change as much in response to GLS inhibition. The tumor-to-blood-activity ratios (T/B) obtained from [18F]4F-Gln PET images matched the distinct glutamine pool sizes of both tumor models at baseline. After a short course of GLS inhibitor treatment, the T/B values increased significantly in TNBC, but did not change in MCF-7 tumors. Across both tumor types and after GLS inhibitor or vehicle treatment, we observed a strong positive correlation between T/B values and tumor glutamine pool size measured using MRS (r2 = 0.71). In conclusion, [18F]4F-Gln PET tracked cellular glutamine pool size in breast cancers with differential GLS activity and detected increases in cellular glutamine pool size induced by GLS inhibitors. This study accomplished the first necessary step toward validating [18F]4F-Gln PET as a PD marker for GLS-targeting drugs. Cancer Res; 77(6); 1476–84. ©2017 AACR.

1 May 2017 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
DMDavid A. Mankoff
David A. Mankoff
MFMichael D. Farwell
Michael D. Farwell
ACAmy S. Clark
Amy S. Clark
DPDaniel A. Pryma
Daniel A. Pryma
An important part of current oncologic practice is the ability to assay cancers for biological features to guide therapeutic choices.1 Cancer biomarkers are traditionally based on in vitro tissue assays.2 Advances in molecular biology and laboratory-based methods have increased the ability to measure cancer biology, including genomics, gene expression, and protein expression.3- 6 Similarly, advances in both technology and cancer science now provide the ability to perform noninvasive cancer assays, including molecular imaging.7 The Society of Nuclear Medicine and Molecular Imaging defines molecular imaging as “the visualization, characterization, and measurement of biological processes at the molecular and cellular levels in humans and other living systems.”8[p18N] Thus far, clinical molecular imaging has been largely radionuclide based in the form of positron emission tomography (PET) or single-photon emission computed tomography. Ongoing work in optical, photoacoustic, ultrasonographic, and hyperpolarized magnetic resonance imaging and spectroscopy offers capabilities highly complementary to radioisotope imaging.9,10

1 January 2016 in Seminars in Nuclear Medicine
Verified
Journal Article
Open access
DMDavid A. Mankoff
David A. Mankoff
CEChristine E. Edmonds
Christine E. Edmonds
MFMichael D. Farwell
Michael D. Farwell
DPDaniel A. Pryma
Daniel A. Pryma
The goal of individualized and targeted treatment and precision medicine requires the assessment of potential therapeutic targets to direct treatment selection. The biomarkers used to direct precision medicine, often termed companion diagnostics, for highly targeted drugs have thus far been almost entirely based on in vitro assay of biopsy material. Molecular imaging companion diagnostics offer a number of features complementary to those from in vitro assay, including the ability to measure the heterogeneity of each patient’s cancer across the entire disease burden and to measure early changes in response to treatment. We discuss the use of molecular imaging methods as companion diagnostics for cancer therapy with the goal of predicting response to targeted therapy and measuring early (pharmacodynamic) response as an indication of whether the treatment has “hit” the target. We also discuss considerations for probe development for molecular imaging companion diagnostics, including both small-molecule probes and larger molecules such as labeled antibodies and related constructs. We then describe two examples where both predictive and pharmacodynamic molecular imaging markers have been tested in humans: endocrine therapy for breast cancer and human epidermal growth factor receptor type 2−targeted therapy. The review closes with a summary of the items needed to move molecular imaging companion diagnostics from early studies into multicenter trials and into the clinic.